NASDAQ:PRTC PureTech Health (PRTC) Stock Price, News & Analysis → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Free PRTC Stock Alerts $28.50 +1.02 (+3.71%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$28.50▼$28.5050-Day Range$23.00▼$30.9152-Week Range$17.08▼$34.00Volume500 shsAverage Volume2,644 shsMarket Capitalization$769.50 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get PureTech Health alerts: Email Address PureTech Health MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.02% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.35Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($3.65) to ($5.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.09 out of 5 starsMedical Sector894th out of 914 stocksPharmaceutical Preparations Industry409th out of 418 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for PureTech Health. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.02% of the outstanding shares of PureTech Health have been sold short.Short Interest Ratio / Days to CoverPureTech Health has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in PureTech Health has recently increased by 4.08%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldPureTech Health does not currently pay a dividend.Dividend GrowthPureTech Health does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PRTC. Previous Next 2.4 News and Social Media Coverage News SentimentPureTech Health has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for PureTech Health this week, compared to 1 article on an average week.Search Interest1 people have searched for PRTC on MarketBeat in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, PureTech Health insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.30% of the stock of PureTech Health is held by insiders.Percentage Held by InstitutionsOnly 0.04% of the stock of PureTech Health is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for PureTech Health are expected to decrease in the coming year, from ($3.65) to ($5.07) per share.Price to Book Value per Share RatioPureTech Health has a P/B Ratio of 1.45. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsWhy Big Pharma is Investing Billions in This BiotechIf you're on the hunt for a great biotech stock under $20... you need to see this video.Watch my exclusive report here>>> About PureTech Health Stock (NASDAQ:PRTC)PureTech Health plc, a clinical stage biotherapeutics company, engages in the discovery, development, and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, currently under Phase 3 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, to inhibit the activity of galectin-9 for treating solid tumors and hematological malignancies. It is also developing LYT-300, an oral allopregnanolone, currently completed Phase 1 stage, to treat depression, anxiety, and related indications; and LYT-310, an oral cannabidiol, currently under preclinical stage, to treat epilepsies and other neurological indications. In addition, the company is developing LYT-503/IMB-150, a non-opioid inflammation targeted disease immunomodulation for the potential treatment of interstitial cystitis, or bladder pain syndrome; and Glyph technology platform, a lymphatic-targeting chemistry platform, which leverages the body's natural lipid absorption and transports the process to orally administer drugs via the lymphatic system. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.Read More PRTC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRTC Stock News HeadlinesApril 27, 2024 | seekingalpha.comPureTech Health plc (PRTC) Q4 2023 Earnings Call TranscriptApril 25, 2024 | finance.yahoo.comPureTech Announces Annual Results for Year Ended December 31, 2023April 27, 2024 | TradeSmith (Ad)The A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...April 21, 2024 | americanbankingnews.comPureTech Health (NASDAQ:PRTC) Shares Gap Down to $26.94April 18, 2024 | businesswire.comPureTech Health: Notice of ResultsApril 16, 2024 | finance.yahoo.comPureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary FibrosisApril 11, 2024 | lse.co.ukUS FDA hands fast track to PureTech head and neck cancer treatmentApril 11, 2024 | markets.businessinsider.comPureTech's LYT-200 Receives FDA Fast Track Designation For Treatment Of Head & Neck CancersApril 27, 2024 | TradeSmith (Ad)The A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...April 11, 2024 | businesswire.comPureTech Receives FDA Fast Track Designation for LYT-200 in Head and Neck CancersApril 9, 2024 | businesswire.comPureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management TransitionsMarch 18, 2024 | businesswire.comBristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 BillionMarch 13, 2024 | finance.yahoo.comPureTech Receives Orphan Drug Designation for LYT-200 in Acute Myeloid LeukemiaFebruary 28, 2024 | finance.yahoo.comAKLI Mar 2024 3.000 callFebruary 27, 2024 | lse.co.ukPureTech notes positive results from Shionogi's EndeavorRx ADHD trialFebruary 27, 2024 | finance.yahoo.comPureTech to Present at Two Upcoming Investor ConferencesFebruary 27, 2024 | businesswire.comPureTech to Present at Two Upcoming Investor ConferencesFebruary 27, 2024 | finance.yahoo.comPureTech Founded Entity Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx ® for Pediatric ADHD Patients in JapanFebruary 27, 2024 | businesswire.comPureTech Founded Entity Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx ® for Pediatric ADHD Patients in JapanFebruary 22, 2024 | finance.yahoo.comPureTech Health plc (PRTC)February 15, 2024 | finance.yahoo.comDown -8.13% in 4 Weeks, Here's Why PureTech Health PLC Sponsored ADR (PRTC) Looks Ripe for a TurnaroundFebruary 9, 2024 | fool.co.ukLSE:PRTC (PureTech Health plc)January 23, 2024 | seekingalpha.comPRTC PureTech Health plcDecember 20, 2023 | msn.comPureTech outlook for 2024December 7, 2023 | finance.yahoo.comPureTech Presents Data from Phase 1 Trial of LYT-200 Targeting Galectin-9 in Solid Tumors at the ESMO Immuno-Oncology Congress 2023November 14, 2023 | msn.comPureTech Phase 2 study for anti-anxiety drug LYT-300 meets primary endpointOctober 11, 2023 | finance.yahoo.comPureTech Presents Data from LYT-100 (Deupirfenidone) Trial in Healthy Older Adults at CHEST Annual MeetingSee More Headlines Receive PRTC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PureTech Health and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/27/2024Next Earnings (Estimated)7/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PRTC CUSIPN/A CIK1782999 Webwww.puretechhealth.com Phone617-482-2333Fax617-482-3337Employees111Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$3.33 million Price / Sales231.08 Cash FlowN/A Price / Cash FlowN/A Book Value$19.64 per share Price / Book1.45Miscellaneous Outstanding Shares27,000,000Free Float25,564,000Market Cap$769.50 million OptionableNot Optionable Beta1.23 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Spencer BallSenior Vice President of Human ResourcesMs. Aleksandra Filipovic M.D.Ph.D., Head of OncologyMs. Cheryl Murphy Ph.D.Head of Grants Management & StrategyMs. Anita Terpstra J.D.Ph.D., Senior VP & Head of Intellectual PropertyMr. Dilip KodiraHead of Data ScienceMs. Anne Burkhardt Ph.D.Head of ResearchDr. Julie Krop M.D. (Age 58)Chief Medical Officer Ms. Joy Bauer M.S.RDN, Chief Nutrition OfficerMr. Robert Lyne (Age 41)Chief Portfolio Officer Mr. William Berry CPAControllerMore ExecutivesKey CompetitorsNurix TherapeuticsNASDAQ:NRIXDianthus TherapeuticsNASDAQ:DNTHLongboard PharmaceuticalsNASDAQ:LBPHBicycle TherapeuticsNASDAQ:BCYCEvolusNASDAQ:EOLSView All Competitors PRTC Stock Analysis - Frequently Asked Questions How have PRTC shares performed in 2024? PureTech Health's stock was trading at $28.18 at the beginning of 2024. Since then, PRTC stock has increased by 1.1% and is now trading at $28.50. View the best growth stocks for 2024 here. When is PureTech Health's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, July 25th 2024. View our PRTC earnings forecast. How do I buy shares of PureTech Health? Shares of PRTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PRTC) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe World's First "$20 Trillion Drug?"Behind the MarketsMan Who Predicted 2008: “This Will be Worse.”AltimetryJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PureTech Health plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.